FATE — Fate Therapeutics Share News
0.000.00%
Last trade - 00:00- $252.82m
- $110.94m
- $6.65m
Brief: Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (Rmat) Designation From FDA For Ft819 To Treat Moderate To Severe Systemic Lupus Erythematosus (Sle)
Brief: Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Brief: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Brief: Fate Therapeutics Presents New Phase 1 Clinical Data Of Ft819 Off-The-Shelf
Brief: Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(C)(4)
Brief: Fate Therapeutics Says Bob Valamehr To Become President, CEO As Of Jan 2025
U.S. RESEARCH ROUNDUP- AMN Healthcare Services, Chart Industries, Home Depot
Fate Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Fate Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Fate Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Broadcom, Xponential Fitness, Northfield Bancorp
U.S. STOCKS ON THE MOVE-Broadcom, Xponential Fitness, Northfield Bancorp
U.S. STOCKS ON THE MOVE-Autodesk, Aaron's Company
Piper Sandler raises Fate to 'overweight' on disease treatment progress
Brief: Fate Therapeutics Inc - On May 30, Edward J. Dulac Iii Provided Notice Of His Resignation From His Position As Chief Financial Officer
Fate Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
Fate Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Agiliti, Domino's Pizza, Krystal Biotech